Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ZIVO Bioscience, Inc. ZIVOW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
24/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

ZIVO Bioscience, Inc. (ZIVOW) is a Biotechnology company in the Healthcare sector, currently trading at $0.04. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $157,220, +468.6%/yr average growth. Net income is $13M (loss), growing at -18%/yr. Net profit margin is -8513.4% (negative). Gross margin is 31.1% (-10.9 pp trend).

Balance sheet: total debt is $254,361 against $2M equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 0.8 (tight liquidity). Debt-to-assets is 15.5%. Total assets: $2M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 21/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

ZIVOW SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ZIVOW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
ZIVOW: +468.6%/yr revenue is, -18%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet ZIVOW: Debt-to-Equity (D/E) ratio 0.17 (conservative), Current ratio is 0.8 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
ZIVOW: Gross margin is 31.1% (-10.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
ZIVOW: Net profit margin is -8513.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.044-0.044
Volume3K
Avg Volume (30D)4.39K
Market Cap$164.23K
Beta (1Y)0.51
Share Statistics
EPS (TTM)-3.92
Shares Outstanding$3.41M
IPO Date2003-12-15
Employees7
CEOJohn Bernard Payne
Financial Highlights & Ratios
Revenue (TTM)$157.22K
Gross Profit$48.95K
EBITDA$-13.36M
Net Income$-13.38M
Operating Income$-13.36M
Total Cash$1.54M
Total Debt$254.36K
Net Debt$-1.29M
Total Assets$1.64M
Price / Earnings (P/E)-0
Price / Sales (P/S)1.04
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS98978N2009

Price Chart

Track all markets on TradingView
ZIVOW
ZIVO Bioscience, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology

People Also View

ZIVO
ZIVO
ZIVO Bioscience, Inc.
$2.12
-3.64%
 GOVXW
GOVXW
GeoVax Labs, Inc.
$0.00
-23.91%
 LEXXW
LEXXW
Lexaria Bioscience Corp.
$0.00
-77.36%
 NLSPW
NLSPW
NLS Pharmaceutics AG
$0.02
-20.94%
 BCTXW
BCTXW
BriaCell Therapeutics Corp.
$0.00
0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message